Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions.
*Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
*Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Location: United States, California, Sunnyvale
Employees: 51-200
Total raised: $203.1M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | OSF Health... | osfhealthc... |
| - | Khosla Ven... | khoslavent... |
| - | MBC BioLab... | mbcbiolabs... |
| - | INITIATE V... | initiate.v... |
| - | StartX | startx.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 16.09.2024 | Series E | $57M | - |
| 18.11.2021 | Grant | $12.1M | - |
| 16.03.2021 | - | $102M | - |
| 13.01.2020 | Series C | $32M | - |
Mentions in press and media 10
| Date | Title | Description |
| 16.09.2024 | Inflammatix: Molecular Diagnostics Company Closes $57 Million In Funding (Series E) | Molecular diagnostics company Inflammatix announced it raised $57 million in Series E funding led by Khosla Ventures and Think.Health. This funding round will support regulatory filing and early commercialization of the company’s lead produ... |
| 12.09.2024 | Inflammatix Raises $57M in Series E Funding | Inflammatix, a Sunnyvale, CA-based molecular diagnostics company, closed a $57m Series E financing. The round was led by Khosla Ventures and Think.Health, with participation from Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesa... |
| 18.11.2021 | Inflammatix Announces Additional $12.1 Million Funding From BARDA for ViraBac EZ Acute Infection Test | Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services... |
| 16.03.2021 | Inflammatix nets $102M to advance its immune system tests for infectious diseases | Inflammatix secured $102 million in new financing to help commercialize its point-of-care diagnostics portfolio aimed at profiling a person’s immune response to quickly ascertain bacterial and viral infections and help curb potential antimi... |
| 16.03.2021 | Inflammatix nets $102M to advance its immune system tests for infectious diseases | Inflammatix secured $102 million in new financing to help commercialize its point-of-care diagnostics portfolio aimed at profiling a person’s immune response to quickly ascertain bacterial and viral infections and help curb potential antimi... |
| 29.10.2020 | Inflammatix Secures Additional $7.4M | BURLINGAME, CA, Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million. >> Click here for more funding data on Inflammatix >> To export Inflammatix funding data to PDF a... |
| 13.01.2020 | Inflammatix Raises $32M in Series C Funding | Inflammatix, a Burlingame, Calif.-based molecular diagnostics company delivering precision medicine at the point of care, raised $32m in Series C financing. The round included participation from existing investors Khosla Ventures, Northpond... |
| 13.01.2020 | Daily funding roundup - January 13th, 2020 | SimpliField raised $11M; Naïo Technologies landed $15.5M; Codagenix secured $20M New Age Meats: New Age Meats a meat from animal cells. New Age Meats has raised $2.7 million in seed round funding led by ff Venture Capital. Other investors i... |
| 10.01.2020 | Inflammatix Announces $32M in Series C | BURLINGAME, CA, Inflammatix announced a $32 million Series C financing. >> Click here for more funding data on Inflammatix >> To export Inflammatix funding data to PDF and Excel, click here Inflammatix, a pioneering molec... |
| - | Inflammatix | “Inflammatix is developing rapid point-of-care diagnostic tests by reading the immune response aimed to help physicians better diagnose acute infections and sepsis.” |